We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Patent Relating To Glaucoma Drug Not Obvious, Board Says

Mealey's (September 24, 2018, 9:54 AM EDT) -- ALEXANDRIA, Va. — In a Sept. 20 final written decision, the Patent Trial and Appeal Board confirmed the patentability of 28 claims of a patented multidose, self-preserved ophthalmic composition for the...
To view the full article, register now.